Results 21 to 30 of about 6,304,439 (300)
Nature Communications, 2023 CDK4/6 inhibitors have shown a synergistic effect with anti-HER2 therapy in hormone receptor (HR)-positive and HER2-positive breast cancer (BC). In this phase 2 study (NCT04293276), we aim to evaluate a dual-oral regimen of CDK4/6 inhibitor dalpiciclib ...
Min Yan +13 more
doaj +1 more source
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Molecular Cancer, 2023 Breast cancer is the second leading cause of death for women worldwide. The heterogeneity of this disease presents a big challenge in its therapeutic management.
Feng Ye +9 more
semanticscholar +1 more source
Immunotherapy in breast cancer: an overview of current strategies and perspectives
npj Breast Cancer, 2023 Recent progress in immunobiology has led the way to successful host immunity enhancement against breast cancer. In triple-negative breast cancer, the combination of cancer immunotherapy based on PD-1/PD-L1 immune checkpoint inhibitors with chemotherapy ...
V. Debien +6 more
semanticscholar +1 more source
Cancer Communications, 2021 Breast cancer is the most commonly diagnosed cancer and leading cause of cancer death among women worldwide but has patterns and trends which vary in different countries.
S. Lei +8 more
semanticscholar +1 more source
Targeting HER2-positive breast cancer: advances and future directions
Nature reviews. Drug discovery, 2022 The discovery of the monoclonal antibody trastuzumab almost 25 years ago revolutionized treatment and drug development for HER2^+ breast cancer. Here, Swain et al.
S. Swain, M. Shastry, E. Hamilton
semanticscholar +1 more source
High expression of Linc00959 predicts poor prognosis in breast cancer
Cancer Cell International, 2019 Background Accumulating studies have focused on the oncogenic roles of the newly identified lncRNAs in human cancers. The aim of this study was to examine the expression pattern of Linc00959 in BC and to evaluate its biological role and clinical ...
Weiru Chi +6 more
doaj +1 more source
Triple-negative breast cancer molecular subtyping and treatment progress
Breast Cancer Research, 2020 Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include high invasiveness,
Li Yin +3 more
semanticscholar +1 more source
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Journal of Clinical Oncology, 2009 UNLABELLED PURPOSE To improve on current standards for breast cancer prognosis and prediction of chemotherapy benefit by developing a risk model that incorporates the gene expression-based "intrinsic" subtypes luminal A, luminal B, HER2-enriched, and ...
J. Parker +19 more
semanticscholar +1 more source
Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women
New England Journal of Medicine, 2021 Background Genetic testing for breast cancer susceptibility is widely used, but for many genes, evidence of an association with breast cancer is weak, underlying risk estimates are imprecise, and reliable subtype-specific risk estimates are lacking ...
L. Dorling +196 more
semanticscholar +1 more source
Nature Communications, 2023 Immunotherapy combined with chemotherapy has been demonstrated to be effective in early triple-negative breast cancer (TNBC). In this single-arm, phase II study with Simon’s two-stage design, we investigated the efficacy and safety of neoadjuvant ...
Chengzheng Wang +11 more
doaj +1 more source